The protective effect of sodium ‐glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease, and type 2 diabetes

ConclusionSGLT2i was safe and prevented further eGFR decline in the patients with type 2 diabetes and advanced renal dysfunction.This article is protected by copyright. All rights reserved.

Source: Journal of Diabetes Investigation - April 25, 2019 Category: Endocrinology Authors: Hideaki Miyoshi, Hiraku Kameda, Kumiko Yamashita, Akinobu Nakamura, Yoshio Kurihara Tags: Clinical Trial Source Type: research